Physician profile
William Robert Arvan
NPI 1972186831
$769.07
in general payments reported to CMS, 2019-2025
9 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.40 · 2022: $27.27 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $481 · Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $481.16 |
| Food and Beverage | $246.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $481.16 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $114.68 | 2025 | Opsumit, Uptravi |
| Genzyme Corporation | $39.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $30.99 | 2022-2025 | Breztri |
| Verona Pharma, INC. | $30.83 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $26.29 | 2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.04 | 2025 | Ofev |
| Currax Pharmaceuticals LLC | $14.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Arvan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.